Siemens Healthineers wins $31.1M ARPA-H grant for stroke robotics
What's the deal? The Advanced Research Projects Agency for Health (ARPA-H)Dealroom has a profile for this one. Try Dealroom → has awarded Siemens HealthineersDealroom has a profile for this one. Try Dealroom → up to $31.1 million over five years to develop autonomous, remote endovascular robotics. The grant targets neurovascular robots that treat acute ischaemic stroke without direct human input.
What's the endgame? Siemens Healthineers is building robots that perform mechanical thrombectomy — a minimally invasive procedure that removes a blood clot from a blocked vessel in the brain — over long distances. Done promptly, the procedure can significantly improve outcomes and cut the risk of long-term disability.
Why now? Access is the problem the grant aims to fix. In the US, more than half the population lives over an hour from a thrombectomy-capable clinic, and only an estimated 12% of 335,000 eligible stroke patients receive the procedure each year, according to ARPA-H.
The details: The funding falls under the ARPA-H Autonomous Interventions and Robotics (AIR) programme, led by programme manager Ileana Hancu. Siemens Healthineers will add $5.4 million as a cost share, bringing total investment to as much as $36.5 million. StrykerDealroom has a profile for this one. Try Dealroom → is acting as a sub-awardee, extending a partnership the two firms formed in 2025.
What could go wrong? The technology is early. Autonomous remote endovascular robotics for stroke is still under development and not commercially available.
"The ARPA-H investment is a big step in advancing autonomous remote endovascular robotics for the benefit of patients and communities around the world," said Philipp Fischer, head of advanced therapies at Siemens Healthineers.
The signal: The grant ranks among the largest of its kind — roughly the 98th percentile of all-time health grants to German companies. It reflects growing state-backed investment in autonomous medical robotics to widen access to time-critical care.
Read more: pharmaphorum
Image credit: Generated with Gemini
